The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to $50 million to Moderna, a US-based biotechnology company, to support the development and initial clinical testing of its mRNA-based vaccine candidate against the Bundibugyo strain of Ebola.
Moderna will utilize its mRNA vaccine platform, the same technology that enabled rapid development of a COVID-19 vaccine during the pandemic. The funding will also facilitate the expansion of manufacturing capabilities and prepare for large-scale Phase 2/3 trials if early testing proves successful. Moderna CEO Stéphane Bancel emphasized the company's commitment, stating, "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
CEPI announced a total commitment of just over $60 million across three vaccine development efforts. Beyond the $50 million to Moderna, CEPI committed $3.2 million to the International AIDS Vaccine Initiative and $8.6 million to the University of Oxford and Serum Institute of India. These funds are directed towards developing vaccines using alternative technologies, highlighting a multi-pronged approach to combating the virus.
The World Health Organization has reported 1,041 cases and 241 deaths in the current outbreak, underscoring the urgency of the situation. The lack of licensed therapeutics or vaccines against the Bundibugyo strain exacerbates the challenges faced by health officials, who must navigate an environment of armed conflict, population mobility, and significant humanitarian needs.
The funding will support Moderna's preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate.
The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged $50 million to Moderna, a US-based biotechnology company, to support the development and initial clinical testing of its mRNA-based vaccine candidate against the Bundibugyo strain of Ebola. This significant investment aims to urgently accelerate the vaccine's progression, providing a much-needed response to the ongoing outbreak in the Democratic Republic of Congo, where health officials are grappling with challenges including delayed detection and the virus's spread in conflict-ridden areas.
Moderna will utilize its mRNA vaccine platform, the same technology that enabled rapid development of a COVID-19 vaccine during the pandemic. The funding will also facilitate the expansion of manufacturing capabilities and prepare for large-scale Phase 2/3 trials if early testing proves successful. Moderna CEO Stéphane Bancel emphasized the company's commitment, stating, "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
CEPI's total commitment to fighting the Bundibugyo ebolavirus outbreak extends beyond Moderna, with additional investments of $3.2 million to the International AIDS Vaccine Initiative and $8.6 million to the University of Oxford and Serum Institute of India. These funds are directed towards developing vaccines using alternative technologies, highlighting a multi-pronged approach to combating the virus.
The World Health Organization has reported 1,041 cases and 241 deaths in the current outbreak, underscoring the urgency of the situation. The lack of licensed therapeutics or vaccines against the Bundibugyo strain exacerbates the challenges faced by health officials, who must navigate an environment of armed conflict, population mobility, and significant humanitarian needs.
With the funding secured, Moderna and its partners can now focus on preclinical development and Phase 1 clinical testing. The successful progression of these stages will be crucial for advancing the vaccine towards larger trials and, ultimately, providing a much-needed medical intervention to control the Ebola outbreak in the Democratic Republic of Congo. This investment not only speeds up the development of a critical vaccine but also enhances global preparedness for future epidemics.
Highlighted text was flagged by the council. Tap to see feedback.
